GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » Dividends per Share

Kiadis Pharma NV (FRA:K3P) Dividends per Share : €0.00 (TTM As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Dividends per Share?

Kiadis Pharma NV's dividends per share for the six months ended in Dec. 2020 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2020 was €0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2020 was 0.00. As of today, Kiadis Pharma NV's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.


Kiadis Pharma NV Dividends per Share Historical Data

The historical data trend for Kiadis Pharma NV's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Dividends per Share Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Dividends per Share
Get a 7-Day Free Trial Premium Member Only - - - - -

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiadis Pharma NV's Dividends per Share

For the Biotechnology subindustry, Kiadis Pharma NV's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Dividend Yield % falls into.



Kiadis Pharma NV Dividends per Share Calculation

Dividends paid to per common share.


Kiadis Pharma NV  (FRA:K3P) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Kiadis Pharma NV's Dividend Payout Ratio for the quarter that ended in Dec. 2020 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2020 )/ EPS without NRI (Q: Dec. 2020 )
=0/ -1.67
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiadis Pharma NV Dividends per Share Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (FRA:K3P) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (FRA:K3P) Headlines

No Headlines